Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
6.70
+0.69 (11.48%)
At close: Feb 6, 2026, 4:00 PM EST
6.70
0.00 (0.00%)
After-hours: Feb 6, 2026, 4:10 PM EST
Aptevo Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Aptevo Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Aptevo Therapeutics.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Roth MKM | Roth MKM | Strong Buy Maintains $199,800 → $106,560 | Strong Buy | Maintains | $199,800 → $106,560 | +1,590,347.76% | Sep 23, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $40,439,520 → $11,721,600 | Buy | Maintains | $40,439,520 → $11,721,600 | +174,949,153.73% | May 13, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $37,509,120 → $29,304,000 | Strong Buy | Maintains | $37,509,120 → $29,304,000 | +437,373,034.33% | May 28, 2021 |
| Piper Sandler | Piper Sandler | Buy Maintains $18,754,560 → $40,439,520 | Buy | Maintains | $18,754,560 → $40,439,520 | +603,574,825.37% | Nov 11, 2020 |
| Roth Capital | Roth Capital | Strong Buy Initiates $98,461,440 | Strong Buy | Initiates | $98,461,440 | +1,469,573,631.34% | Apr 11, 2018 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-98.78
EPS Next Year
-29.38
from -98.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -101.68 | -30.24 | ||||
| Avg | -98.78 | -29.38 | ||||
| Low | -94.90 | -28.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.